


## AMENDMENTS TO THE CLAIMS

The following Listing of Claims, in which deleted text appears in strikethrough or in double brackets, *e.g.*, [[eroor]], and inserted text appears underlined, will replace all prior versions and listings of claims in the application.

### Listing of Claims

Claim 1 (**previously presented**): A compound of the Formula I



wherein

Q<sub>a</sub> is phenyl, and Q<sub>a</sub> may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, trifluoromethyl, cyano, amino, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino and (1-6C)alkoxycarbonyl;

R<sub>1</sub> and R<sub>2</sub> are each independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl; and

Q<sub>b</sub> is pyridyl, and Q<sub>b</sub> may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkoxy, (3-6C)cycloalkyl-(1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, aminosulphonyl, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl and (3-6C)cycloalkylsulphonyl;

and wherein any of the substituents on Q<sub>a</sub> or Q<sub>b</sub> defined hereinbefore which comprise a CH<sub>2</sub> group attached to 2 carbon atoms or a CH<sub>3</sub> group attached to a carbon atom may optionally bear on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more substituents selected from hydroxy, cyano, amino, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino;

or a pharmaceutically-acceptable salt thereof.

Claim 2 (**currently amended**): A compound of the Formula I according to Claim 1 wherein Q<sub>a</sub> is ~~phenyl~~, and Q<sub>a</sub> may optionally bear 1 or 2 substituents selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy;

R<sub>1</sub> and R<sub>2</sub> are each independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl; and

Q<sub>b</sub> is pyridyl, and Q<sub>b</sub> may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl (1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkoxy, (3-6C)cycloalkyl (1-6C)alkoxy, carboxy, (1-6C)alkoxy carbonyl, N-(1-6C)alkyl carbamoyl, N,N-di[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di[(1-6C)alkyl]amino, halogeno (1-6C)alkyl, hydroxy (1-6C)alkyl, (1-6C)alkoxy (1-6C)alkyl, cyano (1-6C)alkyl, amino (1-6C)alkyl, (1-6C)alkylamino (1-6C)alkyl, di[(1-6C)alkyl]amino (1-6C)alkyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, aminosulphonyl, N-(1-6C)alkylsulphamoyl, N,N-di[(1-6C)alkyl]sulphamoyl and (3-6C)cycloalkylsulphonyl;

and wherein any of the substituents on Q<sub>a</sub> or Q<sub>b</sub> defined hereinbefore which comprise a CH<sub>2</sub> group which is attached to 2 carbon atoms or a CH<sub>3</sub> group which is attached to a carbon atom may optionally bear on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more substituents selected from hydroxy, cyano, amino, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino and di[(1-6C)alkyl]amino;

or a pharmaceutically-acceptable salt thereof.

Claim 3 (**currently amended**): A compound of the Formula I according to Claim 1 wherein Q<sub>a</sub> is ~~phenyl~~, and Q<sub>a</sub> may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl and (1-6C)alkoxy; or a pharmaceutically-acceptable salt thereof.

Claims 4-6 (**cancelled**).

Claim 7 (**original**): A compound of the Formula I according to Claim 1 or Claim 2 wherein R<sub>1</sub> and R<sub>2</sub> are each independently selected from hydrogen and (1-6C)alkyl; or a pharmaceutically-acceptable salt thereof.

Claim 8 (**cancelled**).

Claim 9 (**currently amended**): A compound of the Formula I according to Claim 1 selected from: [ ]

N-cyclopropyl-4-methyl-3-{[4-(pyridine-2-ylmethoxy)benzoyl]amino} benzamide;

N-cyclopropyl-4-methyl-3-{[4-(pyridine-3-ylmethoxy)benzoyl]amino} benzamide;

N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-methoxy-4-(pyridin-2-

ylmethoxy)benzamide;

N-cyclopropyl-4-methyl-3- {[3-methyl-4-(pyridin-2-ylmethoxy) benzoyl]amino} benzamide;

N- {5-[(cyclopropylamino)carbonyl]-2-methylphenyl} -3-fluoro-4-(pyridin-2-ylmethoxy)benzamide;

N-cyclopropyl-4-methyl-3- {[3-(pyridin-2-ylmethoxy)benzoyl]amino} benzamide;

3-chloro-N- {5-[(cyclopropylamino)carbonyl]-2-methylphenyl} -4-(pyridin-2-ylmethoxy)benzamide;

N-cyclopropyl-3-( {4-[(4-methoxypyridin-2-yl)methoxy]benzoyl} amino)-4-methylbenzamide;

N-cyclopropyl-4-methyl-3- {[4-(1-pyridin-2-ylethoxy)benzoyl]amino} benzamide;

N-cyclopropyl-3-( {3-[(4-methoxypyridin-2-yl)methoxy]benzoyl} amino)-4-methylbenzamide;

N-cyclopropyl-3-[(4- {5-(hydroxymethyl)pyridine-2-yl}methoxy} benzoyl)amino]-4-methylbenzamide;

N-cyclopropyl-3-[(4- {5-(1-hydroxy-1-methylethyl)pyridin-2-yl}methoxy} benzoyl)amino]-4-methylbenzamide;

N-cyclopropyl-3- {[4-( {5-[(isopropylamino)methyl]pyridin-2-yl}methoxy)benzoyl]amino} -4-methylbenzamide;

N-cyclopropyl-3- {[4-( {5-[(dimethylamino)methyl]pyridin-2-yl}methoxy)benzoyl]amino} -4-methylbenzamide;

methyl 6-( {4-[( {5-[(cyclopropylamino)carbonyl]-2-methylphenyl} amino)carbonyl]phenoxy} methyl) nicotinate;

N-cyclopropyl-3- {[4-( {5-[2-(dimethylamino)ethoxy]pyridin-2-yl}methoxy)benzoyl] amino} -4-methylbenzamide;

N-cyclopropyl-3-( {4-[(5-hydroxypyridin-2-yl)methoxy]benzoyl} amino)-4-methylbenzamide;  
methyl 6-( {4-[( {5-[(cyclopropylamino)carbonyl]-2-methylphenyl)amino)carbonyl]phenoxy} methyl) pyridine-2-carboxylate;

N-cyclopropyl-3-[(4- {6-(hydroxymethyl)pyridin-2-yl}methoxy} benzoyl)amino]-4-methylbenzamide;

N-cyclopropyl-3[(4- {6-(1-hydroxy-1-methylethyl)pyridin-2-yl}methoxy} benzoyl)amino]-4-methylbenzamide;

N-cyclopropyl-3-( {4-[(6- {2-(diethylamino)ethoxy}methyl} pyridin-2-yl)methoxy]benzoyl} amino)-4-methylbenzamide;


N-cyclopropyl-3-( {4-[(6- {2-(dimethylamino)ethoxy}methyl} pyridin-2-yl)methoxy]benzoyl} amino)-4-methylbenzamide;

3-( {4-[(6-bromopyridin-2-yl)methoxy]benzoyl} amino)-N-cyclopropyl-4-methylbenzamide;


N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3,5-difluoro-4-(pyridin-2-ylmethoxy)benzamide;  
 N-cyclopropyl-4-methyl-3-({4-[(6-methylpyridin-2-yl)methoxy]benzoyl} amino)benzamide;  
 N-cyclopropyl-4-methyl-3-({4-[(3-methylpyridin-2-yl)methoxy]benzoyl} amino)benzamide;  
 N-cyclopropyl-3-{[4-({6-[(2-methoxyethyl)amino]pyridin-2-yl} methoxy)benzoyl]amino}-4-methylbenzamide; and  
 N-cyclopropyl-3-({4-[(6-{ [2-(dimethylamino)ethyl]amino} pyridin-2-yl)methoxy]benzoyl} amino)-4-methylbenzamide;  
 or a pharmaceutically-acceptable salt thereof.

Claim 10 (**withdrawn and currently amended**): A process for preparing a compound of the Formula I according to Claim 1, or pharmaceutically-acceptable salt thereof which comprises:

- (a) reacting a benzoic acid of the Formula II, or a activated derivative thereof,




with an amine of the Formula III




under standard amide bond forming conditions, wherein Q<sub>a</sub>, Q<sub>b</sub>, R<sub>1</sub> and R<sub>2</sub> are as defined in Claim 1 or Claim 2 and wherein any functional group is optionally protected, and:

- (i) removing any protecting groups; and  
 (ii) optionally forming a pharmaceutically-acceptable salt; or  
 (b) reacting an acid of the Formula IV, or an activated derivative thereof,



with an aniline of the Formula VI



under standard amide bond forming, wherein  $Q_a$ ,  $Q_b$ ,  $R_1$  and  $R_2$  are as defined in Claim 1 or Claim 2 and wherein any functional group is optionally protected, and:

- (i) removing any protecting groups;
- (ii) optionally forming a pharmaceutically-acceptable salt; or
- (c) for the preparation of a compound of the Formula I wherein a substituent on  $Q_a$  or  $Q_b$  is (1-6C)alkoxy or substituted (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino or substituted (1-6C)alkylamino, the alkylation of an amide derivative of the Formula I wherein a substituent on  $Q_a$  or  $Q_b$  is hydroxy or amino.

**Claim 11 (previously presented):** A pharmaceutical composition which comprises a compound of the Formula I as claimed in any one of claims 1, 2 and 9, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.

**Claims 12-15 (cancelled).**

**Claim 16 (withdrawn and currently amended):** A method for the treatment of rheumatoid arthritis, osteoarthritis, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, multiple sclerosis, AIDS, septic shock, congestive heart failure, ischaemic heart disease or psoriasis in a warm-blooded animal in need thereof comprising administering to said animal an effective amount of a compound of the Formula I as claimed in any one of claims 1, 2 and 9, or a pharmaceutically-acceptable salt thereof.

Claim 17 (**previously presented**): The compound *N*-cyclopropyl-4-methyl-3- {[4-(pyridin-2-ylmethoxy)benzoyl]amino} benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 18 (**previously presented**): The compound *N*-cyclopropyl-4-methyl-3- {[4-(pyridin-3-ylmethoxy)benzoyl]amino} benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 19 (**previously presented**): The compound *N*-{5-(cyclopropylamino)carbonyl}-2-methylphenyl}-3-methoxy-4-(pyridin-2-ylmethoxy) benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 20 (**previously presented**): The compound *N*-cyclopropyl-4-methyl-3- {[3-methyl-4-(pyridin-2-ylmethoxy)benzoyl] amino} benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 21 (**previously presented**): The compound *N*-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy) benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 22 (**previously presented**): The compound 3-chloro-*N*-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-4-(pyridin-2-ylmethoxy) benzamide, or a pharmaceutically-acceptable salt thereof.